Report from London.
Kirby
R
R
D000728:Androgens; D019496:Cancer Vaccines / Q000627:therapeutic use; D019468:Disease Management; D018450:Disease Progression; D006801:Humans; D008297:Male; D015201:Meta-Analysis as Topic; D009376:Neoplasms, Hormone-Dependent / Q000628:therapy; D017410:Practice Guidelines as Topic; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology / Q000628:therapy*; D012008:Recurrence; D006113:United Kingdom; D014481:United States; D014486:United States Food and Drug Administration; D014614:Vaccines, Synthetic / Q000627:therapeutic use
D000728:Androgens; D019496:Cancer Vaccines; D014614:Vaccines, Synthetic; D017430:Prostate-Specific Antigen